FDA: Clot Risk Up for Xeljanz in RA

(MedPage Today) -- Safety signal detected for higher dose of JAK inhibitor in postmarketing trial
Source: MedPage Today Product Alert - Category: Drugs & Pharmacology Source Type: alerts